There have been talks about what would happen once UK leaves EU
which has put lot of QPPV (Qualified Persons Responsible for Pharmacovigilance)
in UK in dilemma as the regulations say that the QPPV should be a part of the
EU, with the impact Brexit it will hit the pharmacovigilance system in UK as EU
would not be obliged to carry out Post marketing surveillance in UK.
Currently June Raine who is chairing the Pharmacovigilance Risk
Assessment Committee ( part of the European Medical Agency, in which there are
two members from each member state) is from the Medicines and healthcare
products regulatory agency (MHRA) of the UK.
There have been discussions about QPPV who still want to be a part
of EU which might eventually lead to a negotiation between EMA and UK to
collaborate pharmacovigilance activities together, as pharmacovigilance is
above politics.
By Joseph Mathew
Sr. Manager- Think i
About us:
We are an organization providing technological solutions and
result oriented quality services in Pharmacovigilance, Clinical Trials,
Medical Writing, Drug Regulatory Affairs and Human Resources.
We provide cloud based software database solutions
for pharmacovigilance which are not only cost effective and
user friendly but also fully validated for quick, easy import, entry and
electronic submissions of adverse event.
For more details, contact us at +91 9560102587
or +91 9810068241
So great work for informing us of the possibilities and following a certain path.
ReplyDeleteMedical Coding Hyderabad